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Abstract 
Objective: Granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony
stimulating factor (GM-CSF) are frequently used in cancer patients to overcome the granulocytopenic
effects of chemotherapy, and also to mobilize the stem cells. The mobilized stem cells are collected
from the peripheral blood and used for transplantation following high doses of chemotherapy.
However, the molecular mechanism by which these colony stimulating factors (CSFs) bring about
proliferation of myeloid precursor cells is not clearly known. Dihydrofolate reductase (DHFR), which
has an established role in DNA synthesis, could be a link between administration of CSF and stem cell
proliferation. The purpose of this study was to investigate whether CSFs induce white cell proliferation
by producing multiple forms of DHFR.
Methods: Twelve patients with non-haematological malignancies were treated with either G-CSF or
GM-CSF to mobilize stem cells. Nine healthy subjects were treated with placebo as controls. Blood
samples were obtained before and after stimulation with CSFs or placebo. White blood cells were
separated and concentrations of both active DHFR and immunoreactive nonfunctional form of DHFR
were determined in their cytoplasm using methotrexate-binding assay and enzyme-linked
immunosorbent assay, respectively. Total leucocytes count (TLC) was also monitored before and after
stimulation with CSFs or placebo.
Results: There was a significant (P<0.05) increase in concentration of immunoreactive nonfunctional
form of DHFR and TLC following stimulation with CSFs. There was an increase in concentration of
active DHFR as well, however, this did not reach statistical significance. In the placebo-treated
subjects, no significant increase in active DHFR, immunoreactive nonfunctional form of enzyme or
TLC was observed. However, it was noticed that the base-line values of active DHFR and
immunoreactive nonfunctional form of enzyme in leucocytes of cancer patients were higher than the
base-line values in leukocytes of normal healthy subjects .
Conclusion:  Our data suggest that colony stimulating factors induce white cell proliferation by
increasing levels of multiple forms of DHFR (JPMA 51:68; 2001).
Introduction 
Colony stimulating factors (CSFs) are haematopoietic growth factors, which stimulate bone marrow
precursor cells to proliferate and differentiate. Because of this property, CSFs have been increasingly
used as therapeutic agents for quick regeneration of white blood cells in patients who are
myelosuppressed following standard or high doses of chemotherapy1. CSFs, such as granulocyte-
macrophage colony stimulating factor (GMCSF) and granulocyte-colony stimulating factor (G-CSF)
have also been used for mobilization of peripheral blood stem cells in a variety of clinical situations2-5.
The mechanism by which these CSFs induce proliferation of stem cells is not well understood.
Dihydrofolate reductase (DHFR), because of its central role in the pathway of de novo DNA synthesis
is involved in cell proliferation6. Forms of the enzyme, which are structurally similar to DHFR but are
functionally inactive, have been reported to be present in human leukemic cells and leucocytes of
patients with nonhematological malignancies7-10. The levels of this immunoreactive nonfunctional
form of DHFR (IRE) have been found to be several fold higher in mid log phase cells
than cells in their stationary growth phase11, suggesting that this form of enzyme may also have a role
in cell proliferation. The objective of this study was to investigate whether or not G-CSF and GM-CSF
induce white cell proliferation through the production of multiple forms of DHFR.
Patients and Methods 
Twelve cancer patients (11 males and I female) who were admitted to The Aga Khan University
Hospital from June 1997 to October 1999 were included in this study. All these patients had non-
haematological malignancies and underwent stem cell mobilization to be treated subsequently with
high doses of chemotherapy. The study was approved by the Human Subject Protection Committee of
the University. Clinical characteristics of these patients are listed in Table 1.
Mean ± SD age was 37.6 ± 14 years. They were treated with either GM-CSF (Molgrastim, Novartis,
Basel, Switzerland) at a dose of 250 mg/m2/day or G-CSF (Filgrastim, Roche, Basel. Switzerland) at a
dose of 5 mg/kg/day subcutaneously for a period of 5-7 days for stem cells mobilization. Ten ml of
blood was removed in a heparinized tube before treatment with CSF and another sample of 10 ml blood
was obtained one day after the last injection of haematopoietic growth factor. Total leucocytes count
(TI.C) was checked on a Coulter Counter in both the samples. From these samples white blood cells
were removed using 3% dextran. Cytoplasms of white blood cells were prepared as described
previously8. These cytoplasmic samples were analyzed for active DHFR by using methotrexate-binding
assay12 and for total immunoreactive DH FR by enzyme-linked immunosorbent assay13 using
antiserum that had previously been defined8. The concentration of IRE in these cytoplasmic samples
was obtained by subtracting the concentration value of active DHFR from the value of total
immunoreactive DHFR. The protein concentration was determined by the method of Lowry et al14.
Nine normal healthy subjects who were matched for age were also included as placebo controls. Two
samples of blood (10 ml each) were obtained (one sample on day I before placebo treatment and
another one on day 8) from these controls. Both the samples were analyzed for TLC. White blood cells
were removed, cytoplasrns were prepared and analyzed for active DHFR and IRE as mentioned above.
The values for TLC, DHFR and IRE are expressed as means ± SD. Statistical analysis of the data was
carried out by using Student’s t-test. The level of statistical significance was P<0.05.
Results 
Figure 1 is a representative diagram, which shows the effect of GM-CSF on concentration values of
IRE and active DI-IFR in leucocyte cytoplasm and on TLC in peripheral blood of a patient with germ
cell tumor. It should be noted that this patient had neutropenia due to prior chemotherapy, which
resolved after two doses of GM-CSF. As shown in the left side of the Figure, there was an increase in
TLC, active DHFR and IRE, while the GMCSF was being administered. However, the increase was not
pronounced (especially in the concentration of active DHFR) when the treatment was discontinued
upon resolution of neutropenia. When GM-CSF was administered again for 6 days (as indicated in the
right side of Figure 1)
to mobilize the stem cells, there was a sharp increase in concentration values of both DHFR and IRE.
The graph as a whole shows a close correlation between the increase in the levels of multiple forms of
DHFR and TLC.
Table 2 shows TLC and concentration values of both active DHFR and IRE in leucocyte cytoplasm
samples of nonneutropenic cancer patients before and after stimulation with CSF and of normal healthy
subjects receiving placebo. There was nearly two fold rise in concentration of active DHFR, three fold
rise in concentration of IRE and nearly five fold increase in TLC following stimulation with CSF. This
increase in both IRE and TLC was found to be statistically significant (P < 0.005). In placebo control
group, no significant change was observed in any of these three parameters.
The base-line values of both active DHFR and IRE in cancer patients were significantly higher (P
<0.025) as compared to the base-line values in normal healthy subjects (active DHFR; 1.05 ± 0.96 ng!
mg vs 0.11 ± 0.03 ng/mg: IRE: 593 ± 461 ng/mg vs 251 ± 182 ng/mg; Table 2).This observation is
consistent with our previously published results8,9. This may be due to the fact that in cancer patients
there is an increased production of cytokines including GM-CSF and GCSF, which in turn might be
responsible for increased levels of DHFR and IRE.
Discussion 
Traditionally, stem cells for bone marrow transplantation have been obtained by bone marrow
aspiration from iliac crest. This process requires general anesthesia. However, recent reports indicate
that the number of circulating stem cells in the peripheral blood can be dramatically increased by
mobilizing them using CSFs, chemotherapeutic agents or both1-5. This greatly facilitates the collection
of stern cells from peripheral blood in numbers sufficient for transplantation and high dose
chemotherapy1,3.
The molecular mechanism by which these haematopoietic growth factors bring about proliferation and
mobilization of stem cells is still obscure, Our findings in this study regarding the effect ofCSFs on
multiple forms of DHFR in non-neutropenic cancer patients are consistent with our previously
published data on effect of CSFs on these forms of enzyme in neutropenic cancer patients15,16. It is not
clear at the present moment whether the increase in levels of multiple forms of DHFR is due to
induction of this enzyme or through increased stabilization of mRNA of DHFR17.
However, our data does indicate. an association between CSF, multiple forms of DI-IFR and white
blood cell proliferation. It also suggests that DHFR might be playing an important role in the CSF
signaling pathway leading to increased proliferation of progenitor white blood cells.
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